Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.10

+0.4%

1:28 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	9/15/2003 10:39:24 AM
From: tom pope	Read Replies (1) of 52153

Another voice heard from. Confusing, isn't it? 10:11 ET GNTA Genta tgt raised to $19 from $13 at Ryan Beck (13.90 -0.35) Although results from recent Phase III study are far from flawless, firm believes the FDA will approve Genasense for the treatment ofmelanoma. This conclusion is based on three primary factors, including (1) a relatively compelling data set that could improve; (2) regulatory precedent set in oncology over the last 6-12 months; and (3) the tremendous unmet medical need in melanoma.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next